Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MGNX vs MESO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MGNX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

MGNX Overall Winner 6-Pillar Tally: MGNX 3 – 3 MESO Matrix Metrics: MGNX 6 – 4 MESO

As of Nov 16, 2026, MacroGenics, Inc. (MGNX) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). MGNX carries a Unified Composite Score of 43.6/100 (HOLD) at $2.02 (61.0x Forward P/E, -21.7% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin).

  • Technical & Structure Timing Caution: MGNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.5); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MGNX vs MESO
MGNX NASDAQ Head-to-Head Winner
MacroGenics, Inc.
Pharmaceutical Preparations
$2.02
-7.95% 1D
Market Cap $145.9M
TTM Revenue $175M
Forward P/E 61.0x
Beta / 30D Vol 1.37β · 148% Vol
Unified Composite Score
43.6 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.4%), weak momentum, RSI 28
RSI-14: 28.5 · SMA20: $2.50 · SMA50: $3.28
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $13.64 · SMA50: $14.22

6-Pillar Scorecard Institutional Category Breakdown (MGNX 3 – 3 MESO)

Columns: Metric · MGNX · MESO
1. Valuation Multiples MGNX
Forward P/E 61.0x N/M
Trailing P/E 61.0x N/M
PEG Ratio 0.01x N/M
EV / Revenue 0.4x 14.1x
2. Growth & Scale MESO
Revenue Growth (YoY) +378.0% +390.7%
Earnings Growth (YoY) -70.4% +0.0%
TTM Revenue (USD) $175M $120M
Market Cap $145.9M $1.7B
3. Profitability & Quality MGNX
Gross Margin -0.7% 80.0%
Operating Margin -21.7% -42.6%
Net Profit Margin -8.3% -47.8%
Return on Equity (ROE) -225.9% -9.9%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$66M -$45M EBITDA
Cash Flow Margin -37.4% -37.1% EBITDA Mgn
Net Cash / Leverage $79M Net Cash $4.38 Book/Sh · -9.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MESO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 52.8% (1st %ile) 76.8% (37th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat MGNX
OpEx & R&D Intensity 21.0% of Rev ($37M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MGNX (6) vs MESO (4)
Institutional Metric MGNX MESO Criterion Row Edge
Market Capitalization
Scale
$145.9M $1.7B Larger Scale MESO
Trailing P/E Ratio
Valuation
61.0x N/M Lower Multiple MGNX
Forward P/E Ratio
Valuation
61.0x N/M Lower Multiple MGNX
Revenue Growth (YoY)
Growth
+378.0% +390.7% Higher Growth MESO
Operating Margin (TTM)
Profitability
-21.7% -42.6% Higher Margin MGNX
Net Profit Margin
Profitability
-8.3% -47.8% Higher Margin MGNX
Return on Equity (ROE)
Capital Efficiency
-225.9% -9.9% Higher ROE MESO
52-Week Range Position
Momentum
19% ($1–$5) 6% ($12–$22) Stronger Trend MGNX
Beta / 30D Volatility
Risk Regime
1.37β · 148% Vol 1.18β · 78% Vol Lower Realized Risk MESO
Unified Institutional Score
Composite Signal
43.6 / 100 (HOLD) 35.5 / 100 (SELL) Higher Composite MGNX
Trailing 12M Revenue (USD)
Operating Scale
$175M $120M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-0.7% 80.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.01x PEG · 0.4x EV/Rev N/M PEG · 14.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($79M Net Cash) -$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MESO +31.59 pp
MGNX: -37.69% · MESO: -6.1%
3M Horizon MESO +25.3 pp
MGNX: -50.49% · MESO: -25.19%
6M Horizon MESO +38.63 pp
MGNX: -53.45% · MESO: -14.82%
1Y Horizon MGNX +42.98 pp
MGNX: +26.56% · MESO: -16.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MGNX vs MESO. Trailing 12-month operating profitability (MGNX -21.7% vs MESO -42.6%) and valuation multiples (MGNX 61.0x vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MGNX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$175M
Gross Margin-0.7%
Op. Margin-21.7%
ROE / Fwd P/E-225.9% · 61.0x
MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MGNX BREAKDOWN
122d in phase · OBV NEUTRAL
Current IV 52.8%
IV Percentile 1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact MGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $145.9M market capitalization and -21.7% operating margin.
OpEx & R&D Reinvestment 21.0% of Rev ($37M)
90D Engineering Disclosures 0 Published
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MGNX vs MESO Key Questions & Quantitative Answers

As of Nov 16, 2026, MacroGenics, Inc. (MGNX) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). MGNX carries a Unified Composite Score of 43.6/100 (HOLD) at $2.02 (61.0x Forward P/E, -21.7% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin). Technical & Structure Timing Caution: MGNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.5); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: MGNX posts +378.0% YoY revenue growth and -70.4% YoY earnings growth on $175M TTM revenue (-0.7% gross margin, -21.7% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, MGNX generates $175M in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, MGNX deploys 21.0% of Rev ($37M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.

MGNX screens cheaper on headline valuation multiples. MGNX trades at 61.0x Forward P/E, 61.0x Trailing P/E, 0.01x PEG, and 0.4x EV/Revenue (-37.4% FCF margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MGNX (-225.9% ROE) versus MESO (-9.9% ROE) capital efficiency.

In options market volatility and institutional positioning, MGNX carries 52.8% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.37β · 148% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.